{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:14:55Z","timestamp":1792721695915,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1136\/ard.2007.080432","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T20:25:42Z","timestamp":1201897542000},"page":"1656-1662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":587,"title":["EULAR recommendations for the management of Beh\u00e7et disease"],"prefix":"10.1016","volume":"67","author":[{"given":"G","family":"Hatemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Houman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P P","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.080432_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/ard.43.6.783","article-title":"Influence of age of onset and patient\u2019s sex on the prevalence and severity of manifestations of Beh\u00e7et\u2019s syndrome.","volume":"43","author":"Yazici","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard.2007.080432_bib3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib4","unstructured":"The AGREE Collaboration,. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. http:\/\/www.agreecollaboration.org (accessed 21 January 2007)."},{"key":"10.1136\/ard.2007.080432_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome.","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.080432_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Beh\u00e7et\u2019s syndrome: effects on long-term prognosis.","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial.","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"3 Suppl 4","key":"10.1136\/ard.2007.080432_bib8","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome.","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.2007.080432_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease.","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.080432_bib10","first-page":"321","article-title":"The efficacy of cyclosporin-a in the treatment of Beh\u00e7et\u2019s disease.","volume":"25","author":"Atmaca","year":"1994","journal-title":"Ophthalmic Surg"},{"key":"10.1136\/ard.2007.080432_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00161239","article-title":"Cyclosporine effects on optic nerve and retinal vasculitis in Beh\u00e7et\u2019s disease.","volume":"80","author":"Chavis","year":"1992","journal-title":"Doc Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/0-306-48382-3_114","article-title":"Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Beh\u00e7et\u2019s disease.","volume":"528","author":"Ermakova","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2007.080432_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0021-5155(99)00025-8","article-title":"Ciclosporin microemulsion preconcentrate treatment of patients with Beh\u00e7et\u2019s disease.","volume":"43","author":"Fujino","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib14","first-page":"210","article-title":"Visual prognosis in patients with Beh\u00e7et\u2019s disease receiving colchicine, systemic corticosteroid or cyclosporin.","volume":"208","author":"Hayasaka","year":"1994","journal-title":"Ophthalmologica"},{"key":"10.1136\/ard.2007.080432_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1021227019915","article-title":"Long-term therapy with low dose cyclosporin A in ocular Beh\u00e7et\u2019s disease.","volume":"105","author":"Ozdal","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF02249016","article-title":"Cyclosporin in Beh\u00e7et\u2019s disease: results in 16 patients after 24 months of therapy.","volume":"13","author":"Pacor","year":"1994","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.1994.10.553","article-title":"Low dose cyclosporin-A therapy in Beh\u00e7et\u2019s disease.","volume":"10","author":"Sajjadi","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"10.1136\/ard.2007.080432_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Beh\u00e7et\u2019s disease.","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1136\/ard.2007.080432_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","article-title":"Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Beh\u00e7et\u2019s disease.","volume":"118","author":"Whitcup","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Beh\u00e7et\u2019s disease.","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/bjo.71.5.387","article-title":"Short term cyclosporin A treatment of Beh\u00e7et\u2019s disease.","volume":"71","author":"Muftuoglu","year":"1987","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/art.1780290420","article-title":"Cyclosporin A is effective, but not safe, in the management of Beh\u00e7et\u2019s disease.","volume":"29","author":"Wechsler","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1136\/ard.2007.080432_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713689008999414","article-title":"Cyclosporin A treatment of Beh\u00e7et\u2019s disease: a long-term study.","volume":"9","author":"Diaz-Llopis","year":"1990","journal-title":"Curr Eye Res"},{"key":"10.1136\/ard.2007.080432_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/26.4.285","article-title":"Cyclosporin A in the treatment of severe Beh\u00e7et\u2019s uveitis.","volume":"26","author":"Binder","year":"1987","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease \u2013 review and basis for recommendations.","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.080432_bib26","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial.","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades\u2013Beh\u00e7et disease.","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.080432_bib28","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis.","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"issue":"4 Suppl 34","key":"10.1136\/ard.2007.080432_bib29","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Beh\u00e7et\u2019s disease.","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease.","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib31","first-page":"427","article-title":"The efficacy of a single dose of infliximab in the treatment of Beh\u00e7et\u2019s disease uveitis.","volume":"23","author":"Arayssi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease.","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Beh\u00e7et\u2019s disease. Long term follow up in four patients.","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"key":"10.1136\/ard.2007.080432_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/0-306-48382-3_112","article-title":"The effect of anti-tumour necrosis factor \u03b1 (infliximab) on sight-threatening uveitis in a patient with Beh\u00e7et\u2019s disease.","volume":"528","author":"Morris","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2007.080432_bib35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","article-title":"Effect of infliximab on threatening panuveitis in Beh\u00e7et\u2019s disease.","volume":"358","author":"Munoz-Fernandez","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.080432_bib36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1345\/aph.1D361","article-title":"Effect of infliximab on refractory uveitis in Beh\u00e7et\u2019s disease.","volume":"38","author":"Sayarlioglu","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2007.080432_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease.","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.080432_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ard.61.6.560","article-title":"Anti-tumour necrosis factor monoclonal antibody treatment for ocular Beh\u00e7et\u2019s disease.","volume":"61","author":"Triolo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon \u03b1-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study.","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2007.080432_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-\u03b12a on ocular and extraocular manifestations of Beh\u00e7et disease: results of an open 4-center trial.","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon \u03b1-2a for the treatment of with sight threatening posterior or panuveitis.","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon \u03b1-2a in severe and refractory uveitis associated with Beh\u00e7et\u2019s disease.","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1136\/ard.2007.080432_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon \u03b1 in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib44","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-\u03b1 therapy in patients with Beh\u00e7et uveitis.","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/0-306-48382-3_103","article-title":"Interferon \u03b1-2a in the treatment of ocular Adamantiades-Beh\u00e7et\u2019s disease.","volume":"528","author":"Krause","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2007.080432_bib46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon \u03b1 treatment on the clinical course of refractory Beh\u00e7et\u2019s disease: an open study.","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"11 Suppl","key":"10.1136\/ard.2007.080432_bib47","first-page":"928","article-title":"Interferon \u03b1 combined with azathioprine for the uveitis of Beh\u00e7et\u2019s disease: an open study.","volume":"4","author":"Hamuryudan","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"10.1136\/ard.2007.080432_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon \u03b1 in Beh\u00e7et disease: review of the literature.","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib49","first-page":"391","article-title":"Treatment of thrombophlebitis of Beh\u00e7et\u2019s disease with low dose cyclosporin A.","volume":"17","author":"Cantini","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib50","unstructured":"Kahraman O, Celebi-Onder S, Kamali S, Inanc M, Ocal L, Aral O, et al. Long-term course of deep venous thrombosis in patients with Beh\u00e7et\u2019s disease. In Proceedings of the American College of Rheumatology 67th Annual Scientific Meeting, Orlando, Florida. New Jersey, USA: Wiley, 2003; S385."},{"key":"10.1136\/ard.2007.080432_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jvs.2005.03.019","article-title":"Long-term outcome after surgical treatment of arterial lesions in Beh\u00e7et disease.","volume":"42","author":"Hosaka","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1136\/ard.2007.080432_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0039-6060(97)90284-1","article-title":"Management of aneurysms in Beh\u00e7et\u2019s syndrome: an analysis of 24 patients.","volume":"121","author":"Tuzun","year":"1997","journal-title":"Surgery"},{"key":"10.1136\/ard.2007.080432_bib53","first-page":"152","article-title":"Abdominal aortic aneurysm in Beh\u00e7et\u2019s disease: new treatment options for an old and challenging problem.","volume":"6","author":"Nitecki","year":"2004","journal-title":"Isr Med Assoc J"},{"key":"10.1136\/ard.2007.080432_bib54","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1148\/radiol.2203001418","article-title":"Aortic and arterial aneurysms in Beh\u00e7et disease: management with stent-grafts \u2013 initial experience.","volume":"220","author":"Park","year":"2001","journal-title":"Radiology"},{"key":"10.1136\/ard.2007.080432_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1583\/1545-1550(2003)010<0075:ETCWIT>2.0.CO;2","article-title":"Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Beh\u00e7et\u2019s disease.","volume":"10","author":"Kwon Koo","year":"2003","journal-title":"J Endovasc Ther"},{"key":"10.1136\/ard.2007.080432_bib56","first-page":"2103","article-title":"Arterial lesions in Beh\u00e7et\u2019s disease. A study in 25 patients.","volume":"22","author":"Le Thi Huong","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/rheumatology\/33.1.48","article-title":"Pulmonary arterial aneurysms in Beh\u00e7et\u2019s syndrome: a report of 24 cases.","volume":"33","author":"Hamuryudan","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib58","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","article-title":"Pulmonary artery aneurysms in Beh\u00e7et syndrome.","volume":"117","author":"Hamuryudan","year":"2004","journal-title":"Am J Med"},{"key":"10.1136\/ard.2007.080432_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF02047208","article-title":"Postoperative recurrence in patients with intestinal Beh\u00e7et\u2019s disease.","volume":"37","author":"Iida","year":"1994","journal-title":"Dis Colon Rectum"},{"key":"10.1136\/ard.2007.080432_bib60","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02235590","article-title":"Long-term clinical course and prognostic factors in intestinal Beh\u00e7et\u2019s disease.","volume":"43","author":"Choi","year":"2000","journal-title":"Dis Colon Rectum"},{"key":"10.1136\/ard.2007.080432_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","article-title":"Remission of intestinal Beh\u00e7et\u2019s disease treated with anti-tumor necrosis factor \u03b1 monoclonal antibody (Infliximab).","volume":"22","author":"Lee","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1136\/ard.2007.080432_bib62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10350-004-6506-4","article-title":"Beh\u00e7et\u2019s ileocolitis: successful treatment with tumor necrosis factor-\u03b1 antibody (infliximab) therapy: report of a case.","volume":"46","author":"Kram","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"10.1136\/ard.2007.080432_bib63","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et\u2019s disease: a case report.","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2007.080432_bib64","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et\u2019s syndrome with chimeric tumour necrosis factor \u03b1 antibody.","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"10.1136\/ard.2007.080432_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1525-1470.2001.018002143.x","article-title":"Successful thalidomide treatment of severe infantile Beh\u00e7et disease.","volume":"18","author":"Brik","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1136\/ard.2007.080432_bib66","first-page":"399","article-title":"A double blind study of colchicine in Beh\u00e7et\u2019s disease.","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"10.1136\/ard.2007.080432_bib67","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome.","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib68","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Beh\u00e7et\u2019s disease. A randomized clinical trial.","volume":"39","author":"Calguneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.080432_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-4362.1991.tb05883.x","article-title":"Treatment of Beh\u00e7et disease with indomethacin.","volume":"30","author":"Simsek","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1136\/ard.2007.080432_bib70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02032350","article-title":"Efficacy of oxaprozin in the treatment of articular symptoms of Beh\u00e7et\u2019s disease.","volume":"3","author":"Takeuchi","year":"1984","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib71","first-page":"493","article-title":"Inefficacy of azapropazone in the acute arthritis of Beh\u00e7et\u2019s syndrome: a randomized, double blind, placebo controlled study.","volume":"13","author":"Moral","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib72","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome.","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.080432_bib73","first-page":"1098","article-title":"Systemic interferon \u03b12b treatment in Beh\u00e7et\u2019s syndrome.","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib74","first-page":"98","article-title":"Short-term trial of eanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study.","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Beh\u00e7et\u2019s disease.","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1136\/ard.2007.080432_bib76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","article-title":"Low dose MTX for progressive neuro-Beh\u00e7et\u2019s disease. A follow-up study for 4 years.","volume":"528","author":"Kikuchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2007.080432_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","article-title":"Chlorambucil in the treatment of uveitis and meningoencephalitis of Beh\u00e7et\u2019s disease.","volume":"76","author":"O\u2019Duffy","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.2007.080432_bib78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-\u03b12a treatment of neuro-Beh\u00e7et disease.","volume":"21","author":"Nichols","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"10.1136\/ard.2007.080432_bib79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro-Beh\u00e7et\u2019s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib80","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et\u2019s disease is successfully treated with etanercept: further evidence for the value of TNF\u03b1 blockade.","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1136\/ard.2007.080432_bib81","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","article-title":"Efficacy of TNF\u03b1 blockade in cyclophosphamide resistant neuro-Beh\u00e7et disease.","volume":"76","author":"Ribi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1136\/ard.2007.080432_bib82","first-page":"181","article-title":"Successful treatment of long-standing neuro-Beh\u00e7et\u2019s disease with infliximab.","volume":"32","author":"Sarwar","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib83","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy.","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2007.080432_bib84","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications \u2013 results of a retrospective analysis of 117 cases.","volume":"25","author":"Kotter","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":"Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A.","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1136\/ard.2007.080432_bib86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.1989.00520390031011","article-title":"Neurologic involvement in Beh\u00e7et\u2019s syndrome. A prospective study.","volume":"46","author":"Serdaroglu","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1136\/ard.2007.080432_bib87","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archderm.135.5.529","article-title":"The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh\u00e7et disease: a randomized, placebo-controlled, double-blind study.","volume":"135","author":"Alpsoy","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2007.080432_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0714.2004.00265.x","article-title":"Clinical and immunological effects of azithromycin in Beh\u00e7et\u2019s disease.","volume":"34","author":"Mumcu","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.1136\/ard.2007.080432_bib89","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3349\/ymj.1997.38.6.444","article-title":"Streptococcal infection in the pathogenesis of Beh\u00e7et\u2019s disease and clinical effects of minocycline on the disease symptoms.","volume":"38","author":"Kaneko","year":"1997","journal-title":"Yonsei Med J"},{"key":"10.1136\/ard.2007.080432_bib90","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial.","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.080432_bib91","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.53.12.828","article-title":"Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Beh\u00e7et\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy.","volume":"53","author":"Gardner-Medwin","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib92","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archderm.1982.01650200004003","article-title":"Thalidomide in the treatment of Beh\u00e7et\u2019s syndrome.","volume":"118","author":"Saylan","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2007.080432_bib93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02054255","article-title":"Treatment of Beh\u00e7et\u2019s disease with thalidomide.","volume":"5","author":"Hamza","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","article-title":"Interferon therapy for Beh\u00e7et\u2019s disease.","volume":"31","author":"Alpsoy","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2007.080432_bib95","first-page":"239","article-title":"Interferon \u03b1-2a in the treatment of Beh\u00e7et\u2019s disease.","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology"},{"key":"10.1136\/ard.2007.080432_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000018427","article-title":"Long-term effects of interferon \u03b12A treatment in Beh\u00e7et\u2019s disease.","volume":"201","author":"Boyvat","year":"2000","journal-title":"Dermatology"},{"key":"10.1136\/ard.2007.080432_bib97","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","article-title":"Efficacy and safety of systemic recombinant interferon-\u03b1 in Beh\u00e7et\u2019s disease.","volume":"243","author":"Georgiou","year":"1998","journal-title":"J Intern Med"},{"key":"10.1136\/ard.2007.080432_bib98","first-page":"1938","article-title":"Interferon-\u03b1 treatment of Beh\u00e7et\u2019s disease.","volume":"25","author":"O\u2019Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.080432_bib99","first-page":"440","article-title":"Adamantiades-Beh\u00e7et disease. Therapeutic administration of systemic recombinant interferon-\u03b1-2a.","volume":"44","author":"Zouboulis","year":"1993","journal-title":"Hautarzt"},{"key":"10.1136\/ard.2007.080432_bib100","doi-asserted-by":"crossref","unstructured":"Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erytematosus (SLE). Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. Published Online First: 15 May 2007. doi:10.1136\/ard.2007.070367.","DOI":"10.1136\/ard.2007.070367"},{"key":"10.1136\/ard.2007.080432_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib102","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/ard.2006.062091","article-title":"EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"66","author":"Zhang","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib103","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib104","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2005.044354","article-title":"EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"66","author":"Combe","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib106","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/ard.2004.028886","article-title":"EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"64","author":"Zhang","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib107","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","article-title":"EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).","volume":"62","author":"Jordan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib108","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.59.12.936","article-title":"EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).","volume":"59","author":"Pendleton","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.080432_bib109","first-page":"132","article-title":"Use and abuse of the controlled clinical trial.","volume":"65","author":"Yazici","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1136\/ard.2007.080432_bib110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/rheumatology\/kel382","article-title":"A cost analysis of Beh\u00e7et\u2019s syndrome in Turkey.","volume":"46","author":"Sut","year":"2007","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.080432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:04:17Z","timestamp":1779249857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724426836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":110,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0003496724426836"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.080432","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of Beh\u00e7et disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.080432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}